fosamprenavir: Clinical Trials

13 trials of fosamprenavir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 3 unknown, 1 terminated. 13 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 313Completed 9, Unknown 3, Terminated 1
Phase 21Completed 1

Follow fosamprenavir: new trials by email Literature Review of fosamprenavir trials Research Report on fosamprenavir

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy
triple therapy, dual therapy - HIV
Phase 3CompletedUniversity Hospital, Tours2242014-12-012025-12-26
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
Efavirenz 600mg, Boosted Lexiva - Human Immunodeficiency Virus Infections
Phase 3CompletedGeorgetown University1012008-07-012013-07-02
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
fosamprenavir/ritonavir - Infection, Human Immunodeficiency Virus I, HIV-1 Infection
Phase 3CompletedViiV Healthcare2122007-03-012012-06-07
Clinical Trial of CNS-targeted HAART (CIT2)
FDA Approved Antiretroviral Therapy (see list below) - HIV Infections
Phase 2 / Phase 3CompletedUniversity of California, San Diego592007-03-012014-04-23
A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects
Half-boosted Fosamprenavir, Full Boosted Fosamprenavir - HIV Infection, Infection, Human Immunodeficiency Virus
Phase 3CompletedGlaxoSmithKline2112006-05-012010-11-05
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
fosamprenavir/ritonavir (700mg/100mg BID), fosamprenavir/ritonavir (1400mg/100mg BID), fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID) - HIV-1
Phase 3TerminatedGlaxoSmithKline1502005-03-012007-11-12
Fosamprenavir Versus Other Protease Inhibitors
Fosamprenavir - Infection, Human Immunodeficiency Virus I
Phase 3CompletedViiV Healthcare3142004-12-142018-04-18
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
LEXIVA (GW433908), Ritonavir, KALETRA - HIV Infection, Infection, Human Immunodeficiency Virus
Phase 3CompletedGlaxoSmithKline8662004-05-012011-05-16
Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR
fosamprenavir, COMBIVIR, ritonavir - HIV Infections
Phase 3CompletedGlaxoSmithKline602002-01-012013-02-12
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
fosamprenavir (GW433908), ritonavir - Infection, Human Immunodeficiency Virus
Phase 3CompletedViiV Healthcare7532001-11-012013-04-19
Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
Lopinavir/Ritonavir, Ritonavir, GW433908 - HIV Infections
Phase 3UnknownGlaxoSmithKline3302001-05-012005-06-24
Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
Ritonavir, Abacavir sulfate, Nelfinavir mesylate - HIV Infections
Phase 3UnknownGlaxo Wellcome6242000-11-012005-06-24
Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy
Abacavir sulfate, Nelfinavir mesylate, Lamivudine - HIV Infections
Phase 3UnknownGlaxo Wellcome2102000-11-012005-06-24

Conditions studied

HIV Infections (7)  ·  Infections (5)  ·  Acquired Immunodeficiency Syndrome (4)  ·  AIDS Dementia Complex (1)  ·  Cognitive Dysfunction (1)

Sponsors

GlaxoSmithKline (5)  ·  ViiV Healthcare (3)  ·  Glaxo Wellcome (2)  ·  Georgetown University (1)  ·  University Hospital, Tours (1)  ·  University of California, San Diego (1)

Countries

United States (10)  ·  France (6)  ·  Italy (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Belgium (3)  ·  Germany (3)  ·  Canada (2)  ·  Portugal (2)  ·  Puerto Rico (2)  ·  Romania (2)  ·  Switzerland (2)  ·  Australia (1)  ·  Austria (1)  ·  Brazil (1)

Top investigators

Princy Kumar, MD (1)

Results publications

PMID 18383194, PMID 20133266, PMID 21126954, PMID 23741991, PMID 24352352, PMID 31350995

NIH funding

R01MH058076 (1)